T A Gaziano
Affiliation: Massachusetts General Hospital
- The global cardiovascular diseases risk pattern in a peri-urban working-class community in South Africa. The Mamre studyKrisela Steyn
Chronic Diseases of Lifestyle Unit, Medical Research Council, P O Box 19070, Tygerberg 7505, South Africa
Ethn Dis 14:233-42. 2004..Such variables could possibly be used for global CVD risk calculations, instead of depending on biochemical estimates for these calculations...
- Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populationsThomas A Gaziano
Divisions of Cardiovascular Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
BMC Med 11:170. 2013..The purpose of this study was to compare the ranking performance of a simple, non-laboratory-based risk score to laboratory-based scores in various South African populations...
- Scaling up chronic disease prevention interventions in lower- and middle-income countriesThomas A Gaziano
Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Annu Rev Public Health 34:317-35. 2013..Continued discussion of proven cost-effective interventions for chronic diseases in the developing world will be useful for improving public health policy...
- Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness analysisJoshua Schulman-Marcus
1Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
BMC Cardiovasc Disord 10:13. 2010..Use of ECG could reduce pre-hospital delay among patients who first present to a general practitioner (GP). We assessed whether performing ECG on patients with acute chest pain would improve long-term outcomes and be cost-effective...
- The global cost of nonoptimal blood pressureThomas A Gaziano
Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Hypertens 27:1472-7. 2009..However, no exhaustive study has been done to evaluate its potential costs, globally. We, therefore, set out to estimate the global economic cost of nonoptimal blood pressure...
- Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohortThomas A Gaziano
Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Lancet 371:923-31. 2008....
- Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in AfricaT A Gaziano
Division of Cardiovascular Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Heart 94:140-4. 2008..It further outlines many of the areas where we know less and must focus our future research in trying to outline cost-effective solutions...
- Scaling up interventions for chronic disease prevention: the evidenceThomas A Gaziano
Harvard Medical School, Boston, MA, USA
Lancet 370:1939-46. 2007..Finally, we review evidence for policy implementation in areas of strong causality or highly probable benefit--eg, changes in personal interventions for diabetes reduction, restructuring of health systems, and wider policy decisions...
- Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure levelThomas A Gaziano
Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Circulation 112:3569-76. 2005..Guidelines based on blood pressure level for initiation of treatment of hypertension may be too costly compared with an approach based on absolute cardiovascular disease (CVD) risk, especially in developing countries...
- Reducing the growing burden of cardiovascular disease in the developing worldThomas A Gaziano
Division of Cardiology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Health Aff (Millwood) 26:13-24. 2007..Despite the burden, cost-effective strategies exist at the population and individual levels for reducing CVD. Integral to all personal intervention strategies is an adequate assessment of the underlying risk of disease...
- Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysisThomas A Gaziano
Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Lancet 368:679-86. 2006..We therefore aimed to establish whether use of evidence-based multidrug regimens for patients at high risk for cardiovascular disease would be cost-effective in low-income and middle-income countries...
- Cardiovascular disease in the developing world and its cost-effective managementThomas A Gaziano
Division of Cardiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Circulation 112:3547-53. 2005
- The South African Hypertension Guideline 2006 is evidence-based but not cost-effectiveThomas A Gaziano
Divisions of Cardiovascular Medicine, and Social Medicine and Health Inequalities, Brigham and Women s Hospital, Boston, MA, USA
S Afr Med J 96:1170-3. 2006
- The Framingham Heart Study's impact on global risk assessmentAsaf Bitton
Division of General Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Prog Cardiovasc Dis 53:68-78. 2010..New studies and risk scores inspired by the Framingham Heart Study need to simplify risk scoring in developing countries so that affordable prevention strategies can be implemented...
- Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study enrollment cohortJ M Gaziano
Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215 1204, USA
J Am Coll Cardiol 35:96-105. 2000..This study examined the relationship between light-to-moderate alcohol consumption and cause-specific mortality...
- Rheumatic fever and rheumatic heart disease: primary prevention is the cost effective optionJames Irlam
Indian J Pediatr 75:86; author reply 86-7. 2008
- Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costsStephen S Lim
Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA 98102, USA
Lancet 370:2054-62. 2007..43 to $0.90 across low-income countries and from $0.54 to $2.93 across middle-income countries. This package could effectively meet three-quarters of the proposed global goal with a moderate increase in health expenditure...
- Global Cardiovascular Disease Policy Model for Screening Prevention and TreatmentThomas A Gaziano; Fiscal Year: 2010..It will incorporate the sensitivity, specificity, costs, and benefits of screening, and the costs and benefits of early intervention. ..